INNOHEP

Dose: 175 anti-Xa IU/kg of body weight
Single Dose: 180 (175)
Frequency: 24 hourly
Route: SC
Instructions: Should be administered for at least 6 days and until the patient is adequately anticoagulated with warfarin (INR at least 2.0 for two consecutive days). Warfarin sodium therapy should be initiated when appropriate (usually within 1-3 days of Tinzaparin Sodium initiation).

.

Tinzaparin Sodium is contraindicated in conditions like Heparin induced thrombocytopenia,Hypersensitivity to any component of product.

The severe or irreversible adverse effects of Tinzaparin Sodium, which give rise to further complications include Cardiac arrhythmias, Granulocytopenia, Angina, Hemorrhage, Hematuria, Thromboembolism.The symptomatic adverse reactions produced by Tinzaparin Sodium are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Abdominal pain, Rashes, Thrombocytopenia, Chest pain, Anemia, UTI, Bleeding, Mild local pain around injection site.

Tinzaparin Sodium is primarily indicated in conditions like Deep vein thrombosis.

No data regarding the interactions of Tinzaparin Sodium was found.

Elevations of SGPT and SGOT Hematocrit Value Elevation in ALT or ASTStool testingComplete blood cell count

Drug should not be given to Cardiac / Hypertensive Patients, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store in a well closed container, Between 15°C-30°C. Protect from Sunlight, Moisture and Heat.

Should not be mixed with other injections or infusions. Should be used with care in patients with a bleeding diathesis, uncontrolled arterial hypertension, or a history of recent gastrointestinal ulceration, diabetic retinopathy and hemorrhage.Tinzaparin Sodium contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but is probably low. Sulfite sensitivity is more frequent in asthmatic people than in non-asthmatic people.